이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Neuromodulation of Sleep and Mood: A Multimodal Biomarker Study of Non-Invasive Vagal Nerve Stimulation (MOSAIC-VNS) (MOSAIC-VNS)

2026년 11월 13일 업데이트: Matthew Macaluso, University of Alabama at Birmingham

The purpose of this study is to learn how non-invasive cervical transcutaneous vagus nerve stimulation (ctVNS) - a treatment given by holding a small hand-held device against the right part of your neck (cervical vagus nerve) - affects sleep, heart rhythm, mood, and certain markers in the blood and some genetic material.

The main questions it aims to answer are:

  1. Will ctVNS enhance both subjective and objective sleep continuity and regularity, improve circadian stability, and increase parasympathetic HRV indices compared with the end-of-sham baseline?
  2. Will improvements in HRV and sleep be associated with greater improvement in standardized depression ratings, with treatment effects mediated in part by improvements in sleep and in part by sleep-independent autonomic mechanisms?
  3. Will ctVNS modify the expression of miRNAs related to sleep, stress, inflammation, and neuroplasticity, and baseline or early-change miRNA profiles, combined with physiological data, and may help distinguish responders from non-responders?

This study lasts about 7 weeks.

Participants will be asked to do the following:

Visit 1/ Baseline (in person):

  • Participants will answer questions about their health, mood, and sleep;
  • have their blood pressure and pulse taken;
  • give about 28 mL (about 6 teaspoons) of blood - 20 mL for the research measurements and 8 mL for routine safety blood tests;
  • be fitted with a wrist device that measures your heart rate, physical activity and sleep; and be given the study device with training on how to use it at home.

This visit will last about 2 hours.

Weeks 1-6 (at home):

  • Participants will use the study device (nerve stimulator) twice a day (morning within 1 hour of waking, and evening within 1 hour of your usual bedtime), each use lasting about 2 minutes;
  • Participants will also need to wear the wrist device day and night;
  • Participants will fill out a short sleep diary each morning.

Visit 2/ Week 2 (in person) and Visit 3/ Week 6 (in person):

  • Participants will repeat the questionnaires and interviews from Visit 1;
  • have their blood pressure and pulse taken;
  • give another blood sample of about 20 mL;
  • have the data from their wrist device downloaded.
  • At each in-person visit after visit 1, their study device will be checked and may be exchanged for another device.

This visit will last about 1.5 - 2 hours.

The investigators will call participants on the phone to check-in at Weeks 1, 3, and 5, and a safety call at Week 7. These phone calls will last about 15 minutes.

연구 개요

상태

아직 모집하지 않음

상세 설명

Major depressive disorder (MDD) and insomnia are highly prevalent, frequently co-occur, and rank among the leading causes of disability worldwide. Up to 80% of people with MDD report significant sleep disturbance, and persistent insomnia predicts higher relapse, poorer treatment response, and greater functional impairment. Autonomic dysregulation, commonly indexed by reduced heart rate variability (HRV), is a shared feature of both conditions and a marker of poor outcome [1], alongside circadian disruption and neuroinflammatory signaling.

Cervical transcutaneous vagus nerve stimulation (ctVNS) engages vagal afferents transcutaneously and may rebalance sympathetic-parasympathetic tone [2,3] and attenuate neuroinflammatory signaling implicated in anxiety and depression [4], with downstream effects on emotion-regulatory circuits and on sleep. Despite this mechanistic plausibility, treatment response to ctVNS remains heterogeneous and mechanistically unclear, and no validated marker identifies who will benefit.

Circulating microRNAs (miRNAs) are stable, accessible post-transcriptional regulators whose peripheral profiles are altered in MDD and may track with diagnosis or relapse risk [5,6]. Preclinical evidence shows that vagus nerve stimulation, which engages the same afferent pathways as ctVNS, modulates stress- and neuroplasticity-related miRNAs (for example, miR-183-3p) [7-9]. Neural-derived exosomes (NDE) isolated from plasma are enriched for signals of neuronal origin and provide a means of interrogating brain-relevant molecular processes from a peripheral blood sample.

Neuromodulation is changing how mental and other central nervous system disorders are treated, but its clinical use is limited by an inability to predict who will respond or why. Three specific gaps slow progress: (1) the pathways linking ctVNS to improvements in sleep and depression remain unclear; (2) no study has combined continuous wearable monitoring with circulating candidate biomarkers to predict response; and (3) the relationship between autonomic change and depression improvement has not been defined.

This study addresses those gaps by combining longitudinal wearable-derived autonomic monitoring, subjective and objective sleep phenotyping, standardized clinical outcomes, and circulating neural-derived exosomal miRNA profiling within a single mechanistic framework. The design separates sleep-mediated from sleep-independent autonomic pathways underlying changes in depression.

A within-subject sham run-in was selected rather than a parallel randomized design because the aim of this pilot is within-subject signal detection and effect-size estimation rather than controlled efficacy testing. The sham run-in establishes a stable, expectancy-adjusted personal baseline and prevents carryover from active stimulation from contaminating that reference. A fixed sham-to-active order partially confounds treatment with time; this limitation is stated explicitly, is mitigated by the end-of-sham anchor and by a group-level autonomic target-engagement check, and is addressed in the planned subsequent randomized, concurrent sham-controlled trial.

Healthy reference participants (Cohort B) are enrolled not as efficacy subjects but to establish normative ranges for HRV, sleep metrics, and candidate miRNA expression, enabling interpretation of disease-related biomarker deviations.

연구 유형

중재적

등록 (추정된)

40

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Alabama
      • Birmingham, Alabama, 미국, 35294
        • University of Alabama at Birmingham (UAB)
        • 수석 연구원:
          • Matthew Macaluso, DO
        • 연락하다:
        • 연락하다:
        • 부수사관:
          • Justin Thomas, PhD
        • 부수사관:
          • Yogesh Dwivedi, PhD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • To be eligible, participants must meet all of the following criteria:

    1. Adults aged 18 through 50 years, inclusive, at the time of consent.

    2. Able to understand and provide written informed consent in English.

    3. Willing and able to wear a study-provided wrist-worn device continuously for approximately 6 weeks and to complete daily sleep diaries.

    4. Willing and able to self-administer the study device twice daily for 6 weeks and to complete a device use log.

    5. Access to a smartphone compatible with the study wearable platform, or willingness to use a study-provided device.

    6. Regular sleep opportunity of at least 6 hours per 24-hour period.

      Cohort A (symptomatic) - additional inclusion criteria:

    7. Insomnia Severity Index (ISI) total score ≥ 15 at screening and confirmed at Visit 1.

    8. MADRS total score ≥ 20 at screening and confirmed at Visit 1.

    9. Meets DSM-5-TR criteria for insomnia disorder on structured clinical interview.

    10. If receiving psychotropic medication or psychotherapy, the regimen has been stable for at least 6 weeks before Visit 1, and the participant and treating clinician agree it will remain stable through Visit 3.

      Cohort B (healthy reference) - additional inclusion criteria:

    11. ISI total score ≤ 7 and MADRS total score ≤ 8 at screening and confirmed at Visit 1.

    12. No current psychiatric disorder or sleep disorder as established by structured diagnostic interview.

    13. No psychotropic medication use within the prior 30 days.

Exclusion Criteria:

  • Participants meeting any of the following criteria are not eligible:

    1. Night-shift or rotating-shift work within the 30 days before Visit 1, or planned during participation.
    2. Travel across more than two time zones within the 14 days before Visit 1, or planned during participation.
    3. Any contraindication to cervical nVNS, including an implanted cervical electrical or metallic device, cardiac pacemaker or implantable cardioverter-defibrillator, any other implanted electronic device, clinically significant carotid atherosclerosis, prior cervical vagotomy, carotid endarterectomy, or cervical surgery at the application site.
    4. Open wound, skin breakdown, active infection, or a dermatologic condition at the intended application site.
    5. Known or suspected pregnancy, or breastfeeding. Participants of childbearing potential will undergo urine pregnancy testing at screening..
    6. Clinically significant cardiac arrhythmia, uncontrolled hypertension (systolic ≥ 160 or diastolic ≥ 100 mmHg on repeated measurement), congestive heart failure, or syncope of unclear cause.
    7. Untreated moderate-to-severe obstructive sleep apnea (STOP-Bang ≥ 5 without evaluation and clearance), restless legs syndrome requiring pharmacologic treatment, narcolepsy, or a circadian rhythm sleep-wake disorder.
    8. Moderate or severe substance or alcohol use disorder within the prior 6 months, or a positive urine drug screen for a non-prescribed substance judged to affect sleep or autonomic measures.
    9. Lifetime diagnosis of bipolar I disorder, schizophrenia, schizoaffective disorder, or another primary psychotic disorder.
    10. Active suicidal ideation with intent or plan (C-SSRS ideation type 4 or 5), any suicide attempt within the prior 6 months, or any clinical presentation requiring urgent or higher-level psychiatric care.
    11. Use of an alternative neuromodulation therapy (implanted VNS, transcranial magnetic stimulation, transcranial direct current stimulation, or electroconvulsive therapy) within the prior 3 months.
    12. Initiation of, or change in dose of, any medication with known substantial effects on heart rate variability (for example, beta-blockers, anticholinergics) within 6 weeks before Visit 1.
    13. Any medical, neurological, or psychiatric condition that, in the investigator's judgment, would compromise participant safety, adherence, or interpretation of study measures.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위화되지 않음
  • 중재 모델: 크로스오버 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
가짜 비교기: Sham Run-In (Weeks 1-2)

Inactive sham stimulation, twice daily. Each participant receives first.

sham run-in ctVNS

활성 비교기: Active stimulation (Weeks 3-6)

Blinded active cervical nVNS, twice daily. Each participant receives second.

ctVNS

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Primary physiologic endpoint as change in parasympathetic heart rate variability (nocturnal RMSSD).
기간: Change from Visit 2 (week 2) to Visit 3 (week 6).

Linear mixed-effects models estimating within-subject physiologic change from the end-of-sham anchor (week 2), with participant as a random effect and phase, time, cohort, age, sex, and body mass index as fixed effects.

Change from Visit 2 (week 2) to Visit 3 (week 6).
Primary clinical endpoint as change in Insomnia Sleep Index (ISI) total score in Cohort A (affected).
기간: Change from Visit 2 (week 2) to Visit 3 (week 6).

The ISI is a 7-item self-report questionnaire used to assess nature, severity and impact of insomnia over previous 2 weeks. Each item is rated 0-4 , with total score range of 0-28. Higher score indicates greater insomnia severity. Response is defined as ≥ 50% reduction in ISI total score or remission (ISI ≤ 7).

Change from Visit 2 (week 2) to Visit 3 (week 6).

2차 결과 측정

결과 측정
측정값 설명
기간
Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score in Cohort A (affected) from Visit 2 to Visit 3.
기간: Change from Visit 2 (week 2) to Visit 3 (week 6).

The MADRS is a 10-item clinician rated scale used to assess severity of depression symptoms. Each item is scored from 0 to 6, with total possible score range of 0-60. A total score of 0-8 indicates no depression, and 8 or above would indicate some level of depression ranging from mild to severe. Higher score indicates greater depression symptoms.

Change from Visit 2 (week 2) to Visit 3 (week 6).
Differential expression of neural-derived exosomal microRNAs from Visit 2 to Visit 3.
기간: Change from Visit 2 (week 2) to Visit 3 (week 6).

Differential expression screening with Benjamini-Hochberg false discovery rate control (q < 0.05), followed by exploratory penalized regression classifiers with nested cross-validation and reporting of optimism-corrected performance.

Change from Visit 2 (week 2) to Visit 3 (week 6).

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Matthew Macaluso, DO, University of Alabama at Birmingham

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2028년 9월 30일

연구 완료 (추정된)

2029년 1월 1일

연구 등록 날짜

최초 제출

2026년 10월 16일

QC 기준을 충족하는 최초 제출

2026년 11월 13일

처음 게시됨 (실제)

2026년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 13일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • STUDY00000060
  • TEAMSCI9617 (기타 보조금/기금 번호: UAB Heersink School of Medicine (Team Science Award))

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다